New nano-material enables label-free protein-protein interaction analysis on a standard absorbance plate-reader Brussels, December 1, 2011 – Pharma Diagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of SoPRano™ GNR (Gold Nano-Rod) assay kits for screening and analysis of protein-protein interactions.

Label-free assay technology receives New Product Award Designation from panel of scientific and industry specialists Brussels, April 12, 2011 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today that their SoPRano™ technology has won its third award in 12 months.

Three new methods expand options for coupling proteins to gold nanoparticles, broaden applicability Brussels, March 17, 2011 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of three new methods for coupling proteins to the gold nanoparticles used with PharmaDiagnostics’ SoPRano™ technology.

Label-free screening company strengthens executive teamwith former pharma department head Brussels, March 3, 2011 - PharmaDiagnostics NV, a company developing andmarketing a broadly-enabling, label-free screening technology that uniquelydoes not require specialized instrumentation, announces today the appointment of Dr Sylviane Boucharens as director of assay development.

Label-free assays will enable more informed decision-making earlier in the discovery process Brussels, February 17, 2011 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized instrumentation, announces today that it has been awarded a European patent for its innovative SoPRano ADME assays (absorption, distribution, metabolism, and excretion of drug compounds).

Label-free assay technology garners unprecedented second successive endorsement from broad range of pharmaceutical industry and academic delegates at recent ELRIG DD2010 conference. Brussels, October 21, 2010 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today that it has again won first prize for the most innovative technology at a highly-focussed gathering of industry and academic drug discovery experts.

Pharmaceutical and biotechnology companies can now use SoPRano™ to develop their own label-free assays Brussels, August 26, 2010 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of its SoPRano™ assay kit, SoPRano CA1.

Co-founder and former CEO of Biacore brings world-class experience to company offering label-free screening to a wider range of researchers Brussels, March 1, 2010 - PharmaDiagnostics NV, a company developing and marketing a broadly enabling, label-free screening technology that uniquely does not require specialized equipment, announces today that it has appointed Ulf Jönsson as non-executive director. Jönsson was a cofounder and CEO of Biacore, the market leader in label-free screening and now part of GE Healthcare.

PharmaDiagnostics debuts label-free screening platform including assays for ADME and physico-chemical properties at Screening Europe in Barcelona, February 11 – 12 (stand 46) Brussels, February 8, 2010 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today the launch of SoPRano, a high-performance set ofscreening tools to accelerate the drug discovery process for pharmaceutical and biotechnology companies.

Advance will enable PharmaDiagnostics to maximize commercial potential of label-free screening technology Brussels, December 11, 2009 - PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized equipment, announces today that it has been granted a US patent covering its nanoparticle/conductive polymer composites. The patent is entitled “Stable metal/conductive polymer composite colloids and methods for making and using the same”.